Vice President & General Manager

An experienced international executive leader with a proven track record in full P&L management and strategic portfolio development in the biotech and biopharma sectors

Specializes in product launch readiness and lifecycle management, with expertise in rare diseases, orphan drugs, and multiple therapeutic domains, driving significant revenue growth

Adept at digital transformation and AI-enabled solutions, fostering high-performance teams and innovative strategies in challenging and regulated environments

Demonstrates strong leadership in crisis management, organizational restructuring, and developing company value propositions through digitalization and ESG initiatives

Accountable for the full P&L with 150M € revenues within the Hematology Rare Disease & Immunology portfolio by growing a sustainable and profitable business with a 19% revenues growth YoY, and a double digit growth in profit contribution

Leading 100 people - 11 direct reports (Leadership Team Directors, Country Manager)

Launch readiness strategy for 3 blockbusters in Hemophilia, Oncoematology, Nephrology

LCM in Immunology

Organizational restructuring

Consistently developing Company value proposition and driving Innovation by developing Digitalization, Artificial Intelligence, ESG, DEI, Crisis Management

Accountable for the Italian P&L by growing the Business with a 17% YoY revenue growth

Strongly Positioning in the Onco-hematology arena by developing preclinical, clinical and commercialization workflow with CAR T-cells

Consistently developing Medical Affairs, R&D, Pricing and reimbursement, Market Access, Regulatory and Launch strategy for Biomedicine CAR T-cells launch

Successful ‘Crisis management’ in a pandemic era by implementing a digitalization strategy transformation

Coaching, developing and mentoring High performing Teams with a change management innovative approach by focusing on diversities, inclusion, integration and a positive mindset in the CoVid-19 pandemic era

Developed and finalized AI and Machine Learning Projects, Orchestrated Customer Engagement (OCE) support projects for Healthcare and Biopharma Companies in a strongly human data science driven context

Data privacy and compliance

Leading Data science, Marketing, Digital communication Team

Interm leading High Performance multi-functional SC departments of 20 people including Sales, Marketing, Market Access, Commercial Excellence and generating Revenues of approx. 19 M € for Italy managing variable spend Bdg of 2 M €

Accountable for the Commercial P&L for both the Business Units in the above geographic areas overachieving. Profitability Goals: increased in 2 years Rev Growth 12% YoY in a mature asset

P&R negotiation with regulatory authorities for Neuroscience and Rare Disease with an optimal market access strategy

Successfully positioning and fostering a START UP in Italy and EU market, establishing Vision, Mission, Medical strategy, Market Access Strategy and P&R, Marketing Strategy, Communication strategy, Hiring the full Italian Team. Set up Governance, Compliance, Legal structure according with local regulation

Launch in Italy and EU – strategy Italy & EU

Achieved Revenues of 12M € with YoY growth >25% in 2015 - CAGR= 56% from 2012-2016

Accountable for the Italian P&L: Early Break even point achieved after 2.5 years

Developed and strongly established a Cross functional Team culture

Co-led EU5 Commercial strategy from 2012-2016: Commercial, Market Access, Medical Affairs and R&D strategy

Various growing Leadership roles in Sales & Marketing at Italian & International level in Cardiovascular, Respiratory, Metabolic, Gastroenterology, Oncology

Launched 3 blockbusters